Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2172667 | Cytotherapy | 2007 | 11 Pages |
Abstract
These data suggest that most leukemic progenitors of CD34+ patients do not express CD33. In contrast, CD34â AML primitive leukemic progenitors may be CD33+. CD34â AML patients could potentially benefit most from CD33-targeted therapies or purging.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
S.M. Vercauteren, R. Zapf, H.J. (Dr),